UCB, Dr. Reddy's, Others Settle Keppra Litigation

Law360, New York (October 5, 2007, 12:00 AM EDT) -- Belgian pharmaceutical company UCB has struck settlement deals with Mylan Pharmaceuticals Inc., Dr. Reddy's Laboratories Inc. and Cobalt Pharmaceuticals Inc., resolving pending patent litigation in Georgia over UCB's epilepsy treatment Keppra.

The settlement agreements pertain to cases Brussels-based UCB Societe Anonyme and its U.S. subsidiary UCB Pharma Inc. filed in the northern district of Georgia.

The pact with Mylan will allow Mylan to market 250 mg, 500 mg and 750 mg generic levetiracetam—the active ingredient in Keppra—tablets in the U.S. beginning on Nov. 1, 2008 provided...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.